![Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/3-Table2-1.png)
Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin | Scientific Reports Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-023-32426-6/MediaObjects/41598_2023_32426_Fig1_HTML.png)
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin | Scientific Reports
![PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar](https://ai2-s2-public.s3.amazonaws.com/figures/2017-08-08/92e61d19dc92e499c7b7b01818ac923837d9f518/2-Table2-1.png)
PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar
![Biclonal plasma cell myeloma with the simultaneous appearance of both secretory lambda and nonsecretory kappa monoclonal light chains Biclonal plasma cell myeloma with the simultaneous appearance of both secretory lambda and nonsecretory kappa monoclonal light chains](https://www.degruyter.com/document/doi/10.1515/cclm-2016-0364/asset/graphic/j_cclm-2016-0364_fig_002.jpg)
Biclonal plasma cell myeloma with the simultaneous appearance of both secretory lambda and nonsecretory kappa monoclonal light chains
![IJMS | Free Full-Text | Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis IJMS | Free Full-Text | Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis](https://www.mdpi.com/ijms/ijms-22-07470/article_deploy/html/images/ijms-22-07470-g002.png)
IJMS | Free Full-Text | Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis
![Patient 1 with a history of IgG kappa multiple myeloma presented with... | Download Scientific Diagram Patient 1 with a history of IgG kappa multiple myeloma presented with... | Download Scientific Diagram](https://www.researchgate.net/publication/31292541/figure/fig1/AS:309933695356934@1450905359416/Patient-1-with-a-history-of-IgG-kappa-multiple-myeloma-presented-with-acute-renal.png)
Patient 1 with a history of IgG kappa multiple myeloma presented with... | Download Scientific Diagram
![PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar](https://ai2-s2-public.s3.amazonaws.com/figures/2017-08-08/92e61d19dc92e499c7b7b01818ac923837d9f518/2-Table1-1.png)